Curated News
By: NewsRamp Editorial Staff
September 16, 2026
Pancreatic Cancer Hijacks Blood Clotting to Evade Immune System
TLDR
- Mount Sinai found pancreatic cancer uses blood clotting to evade immunity, offering a first-mover advantage in immunotherapy.
- Mount Sinai researchers discovered pancreatic cancer cells exploit the blood clotting system to hide from immune attack.
- Mount Sinai's discovery could improve immunotherapy for pancreatic cancer, offering hope to patients with a 13% survival rate.
- Pancreatic cancer hijacks wound healing to evade the immune system, a clever trick that Mount Sinai researchers have now uncovered.
Impact - Why it Matters
This discovery matters because pancreatic cancer’s ability to evade the immune system has long been a major barrier to effective treatment. By identifying the blood clotting system as a key player in this evasion, researchers have opened a promising new target for immunotherapy. If therapies can disrupt this mechanism, they could make existing immunotherapies more effective and potentially improve survival rates for one of the most lethal cancers. The implications extend beyond pancreatic cancer, as other cancers may use similar wound-healing mechanisms to escape immune detection. Patients and investors alike should watch for further developments, as companies like Calidi Biotherapeutics and others may translate these findings into novel treatments, offering new hope where few options currently exist.
Summary
New research from Mount Sinai’s Icahn School of Medicine has uncovered a key mechanism that pancreatic cancer cells use to evade the immune system. The study, led by senior author Brian D. Brown, PhD, Professor of Genetic Engineering, reveals that pancreatic cancer hijacks the blood clotting system to shield itself from immune attack. Because of this evasion, pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate of only 13%. The findings suggest that targeting this pathway could improve immunotherapy outcomes for patients.
The news release also notes that researchers at companies such as Calidi Biotherapeutics Inc. (NYSE American: CLDI) may offer valuable perspectives on whether similar strategies could be applied to other cancers or enhance existing treatments. This discovery opens new avenues for developing therapies that disrupt the cancer’s ability to exploit wound-healing mechanisms. Read More>>
The announcement was distributed by TechMediaWire, a specialized communications platform focused on pioneering companies in technology and life sciences. TechMediaWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The platform aims to connect public and private companies with investors, journalists, and the public. For more information, visit www.TechMediaWire.com. To receive SMS alerts, text “TECH” to 888-902-4192 (U.S. mobile phones only).
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Pancreatic Cancer Hijacks Blood Clotting to Evade Immune System
